Protein Lactylation in Cancer: Mechanisms and Therapeutic Targets

Abstract

The Warburg effect states that cancer cells preferentially undergo aerobic glycolysis, producing lactate as a key metabolic byproduct. Lactate acidifies the tumor microenvironment (TME) and serves as a signaling molecule and substrate for lysine lactylation (Kla), a novel posttranslational modification (PTM) discovered in 2019 that links glycolytic metabolism to epigenetic and proteomic reprogramming. The reversible modification of histones and nonhistone proteins orchestrates oncogenic adaptation and drives tumor progression. However, gaps persist in our understanding of the multifactorial regulation of lactylation and its translational potential in overcoming tumor heterogeneity and resistance. This review highlights the emerging roles of lactylation in cancer therapies, including the enhancement of DNA repair mechanisms during chemotherapy, stabilization of key signaling effectors upon targeted therapy, and promotion of an immunosuppressive TME in immunotherapy. We further examined regulatory factors associated with lactylation, from competitive PTMs and genetic mutations to microbial influences and environmental signals. Additionally, we discuss the therapeutic potential of targeting lactylation via indirect modulators currently under investigation and the visualization of lactate and lactylation modifications. By synthesizing these insights, this review highlights lactylation as a reversible metabolic-epigenetic axis for precision oncology, enabling predictive biomarkers, combination strategies, and novel interventions to address the dynamic challenges of cancer.

Keywords

lactate / lactylation / metabolic-epigenetic axis / precision oncology

References

[1] O. Warburg, “On the Origin of Cancer Cells,” Science 123, no. 3191 (1956): 309–314.

[2] S. M. Fendt, “100 Years of the Warburg Effect: A Cancer Metabolism Endeavor,” Cell 187, no. 15 (2024): 3824–3828.

[3] Y. Wang and G. J. Patti, “The Warburg Effect: A Signature of Mitochondrial Overload,” Trends in Cell Biology 33, no. 12 (2023): 1014–1020.

[4] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science 324, no. 5930 (2009): 1029–1033.

[5] X. Luo, Z. Li, L. Chen, et al., “Monocarboxylate Transporter 1 in the Liver Modulates High-Fat Diet-Induced Obesity and Hepatic Steatosis in Mice,” Metabolism: Clinical and Experimental 143 (2023): 155537.

[6] O. Elhanani, R. Ben-Uri, and L. Keren, “Spatial Profiling Technologies Illuminate the Tumor Microenvironment,” Cancer Cell 41, no. 3 (2023): 404–420.

[7] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575–580.

[8] D. Zhang, J. Gao, Z. Zhu, et al., “Lysine L-Lactylation Is the Dominant Lactylation Isomer Induced by Glycolysis,” Nature Chemical Biology 21, no. 1 (2025): 91–99.

[9] S. K. Dai, P. P. Liu, X. Li, L. F. Jiao, Z. Q. Teng, and C. M. Liu, “Dynamic Profiling and Functional Interpretation of Histone Lysine Crotonylation and Lactylation During Neural Development,” Development 149, no. 14 (2022): dev200049.

[10] X. Zhang, Y. Liu, and N. Wang, “Dynamic Changes in Histone Lysine Lactylation During Meiosis Prophase I in Mouse Spermatogenesis,” PNAS 122, no. 7 (2025): e2418693122.

[11] Y. Chen, J. Wu, L. Zhai, et al., “Metabolic Regulation of Homologous Recombination Repair by MRE11 Lactylation,” Cell 187, no. 2 (2024): 294–311.

[12] H. Chen, Y. Li, H. Li, et al., “NBS1 Lactylation is Required for Efficient DNA Repair and Chemotherapy Resistance,” Nature 631, no. 8021 (2024): 663–669.

[13] L. Bian, Y. Meng, M. Zhang, and D. Li, “MRE11-RAD50-NBS1 Complex Alterations and DNA Damage Response: Implications for Cancer Treatment,” Molecular Cancer 18, no. 1 (2019): 169.

[14] J. D. Rabinowitz and S. Enerback, “Lactate: The Ugly Duckling Of Energy Metabolism,” Nature Metabolism 2, no. 7 (2020): 566–571.

[15] T. B. S. Miholjcic, H. Halse, M. Bonvalet, et al., “Rationale for LDH-Targeted Cancer Immunotherapy,” European Journal of Cancer 181 (2023): 166–178.

[16] J. J. Thompson, J. McGovern, C. S. D. Roxburgh, J. Edwards, R. D. Dolan, and D. C. McMillan, “The Relationship Between LDH and GLIM Criteria for Cancer Cachexia: Systematic Review and Meta-Analysis,” Critical Reviews in Oncology/Hematology 199 (2024): 104378.

[17] S. Ganapathy-Kanniappan and J. F. Geschwind, “Tumor Glycolysis as a Target for Cancer Therapy: Progress and Prospects,” Molecular Cancer 12 (2013): 152.

[18] Z. Kooshan, L. Cárdenas-Piedra, J. Clements, and J. Batra, “Glycolysis, the Sweet Appetite of the Tumor Microenvironment,” Cancer Letters 600 (2024): 217156.

[19] J. Chen, Z. Huang, Y. Chen, et al., “Lactate and Lactylation in Cancer,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 38.

[20] M. Singh, J. Afonso, D. Sharma, et al., “Targeting Monocarboxylate Transporters (MCTs) in Cancer: How Close Are We to the Clinics?,” Seminars in Cancer Biology 90 (2023): 1–14.

[21] V. L. Payen, M. Y. Hsu, K. S. Radecke, et al., “Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter,” Cancer Research 77, no. 20 (2017): 5591–5601.

[22] V. L. Payen, E. Mina, V. F. Van Hee, P. E. Porporato, and P. Sonveaux, “Monocarboxylate transporters in cancer,” Molecular Metabolism 33 (2020): 48–66.

[23] R. Le Floch, J. Chiche, I. Marchiq, et al., “CD147 Subunit of Lactate/H+ Symporters MCT1 and Hypoxia-Inducible MCT4 Is Critical for Energetics and Growth of Glycolytic Tumors,” Proceedings of the National Academy of Sciences of the USA 108, no. 40 (2011): 16663–16668.

[24] P. Apostolova and E. L. Pearce, “Lactic Acid and Lactate: Revisiting the Physiological Roles in the Tumor Microenvironment,” Trends in Immunology 43, no. 12 (2022): 969–977.

[25] V. Estrella, T. Chen, M. Lloyd, et al., “Acidity Generated by the Tumor Microenvironment Drives Local Invasion,” Cancer Research 73, no. 5 (2013): 1524–1535.

[26] C. M. Worsley, R. B. Veale, and E. S. Mayne, “The Acidic Tumour Microenvironment: Manipulating the Immune Response to Elicit Escape,” Human Immunology 83, no. 5 (2022): 399–408.

[27] J. W. Wojtkowiak, D. Verduzco, K. J. Schramm, and R. J. Gillies, “Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment,” Molecular Pharmaceutics 8, no. 6 (2011): 2032–2038.

[28] L. Feng, Z. Dong, D. Tao, Y. Zhang, and Z. Liu, “The Acidic Tumor Microenvironment: A Target for Smart Cancer Nano-Theranostics,” National Science Review 5, no. 2 (2017): 269–286.

[29] A. Tafech and A. Stéphanou, “On the Importance of Acidity in Cancer Cells and Therapy,” Biology 13, no. 4 (2024): 225.

[30] Y. Xie, H. Hu, M. Liu, et al., “The Role and Mechanism of Histone Lactylation in Health and Diseases,” Frontiers in Genetics 13 (2022): 949252.

[31] J. Qu, P. Li, and Z. Sun, “Histone Lactylation Regulates Cancer Progression by Reshaping the Tumor Microenvironment,” Frontiers in Immunology 14 (2023): 1284344.

[32] Q. Meng, H. Sun, Y. Zhang, et al., “Lactylation Stabilizes DCBLD1 Activating the Pentose Phosphate Pathway to Promote Cervical Cancer Progression,” Journal of Experimental & Clinical Cancer Research: CR 43, no. 1 (2024): 36.

[33] X. Hu, X. Huang, Y. Yang, et al., “Dux Activates Metabolism-Lactylation-MET Network During Early iPSC Reprogramming With Brg1 as the Histone Lactylation Reader,” Nucleic Acids Research 52, no. 10 (2024): 5529–5548.

[34] Z. Zong, F. Xie, S. Wang, et al., “Alanyl-tRNA Synthetase, AARS1, Is a Lactate Sensor and Lactyltransferase That Lactylates p53 and Contributes to Tumorigenesis,” Cell 187, no. 10 (2024): 2375–2392.

[35] Z. Niu, C. Chen, S. Wang, et al., “HBO1 Catalyzes Lysine Lactylation and Mediates Histone H3K9la to Regulate Gene Transcription,” Nature Communications 15, no. 1 (2024): 3561.

[36] C. Moreno-Yruela, D. Zhang, W. Wei, et al., “Class I Histone Deacetylases (HDAC1-3) are Histone Lysine Delactylases,” Science Advances 8, no. 3 (2022): eabi6696.

[37] Z. Fan, Z. Liu, N. Zhang, et al., “Identification of SIRT3 as an Eraser of H4K16la,” iScience 26, no. 10 (2023): 107757.

[38] G. Zhai, Z. Niu, Z. Jiang, et al., “DPF2 Reads Histone Lactylation to Drive Transcription and Tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 50 (2024): e2421496121.

[39] X. W. Zhang, L. Li, M. Liao, et al., “Thermal Proteome Profiling Strategy Identifies CNPY3 as a Cellular Target of Gambogic Acid for Inducing Prostate Cancer Pyroptosis,” Journal of Medicinal Chemistry 67, no. 12 (2024): 10005–10011.

[40] M. G. Cho, R. J. Kumar, C. C. Lin, et al., “MRE11 Liberates cGAS From Nucleosome Sequestration During Tumorigenesis,” Nature 625, no. 7995 (2024): 585–592.

[41] M. Beltran-Visiedo, S. Balachandran, and L. Galluzzi, “MRE11 Mobilizes CGAS and Drives ZBP1-Dependent Necroptosis,” Cell Research 34, no. 7 (2024): 477–478.

[42] X. He, Y. Li, J. Li, et al., “HDAC2-Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple-Negative Breast Cancer,” Advanced Science 12, no. 14 (2025): e2413121.

[43] P. Gediya, P. K. Parikh, V. K. Vyas, and M. D. Ghate, “Histone Deacetylase 2: A Potential Therapeutic Target for Cancer and Neurodegenerative Disorders,” European Journal of Medicinal Chemistry 216 (2021): 113332.

[44] Q. Yue, Z. Wang, Y. Shen, et al., “Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention,” Advanced Science 11, no. 19 (2024): e2309290.

[45] J. Zhao, S. Yang, X. Cui, et al., “A Novel Compound EPIC-0412 Reverses Temozolomide Resistance via Inhibiting DNA Repair/MGMT in Glioblastoma,” Neuro-Oncology 25, no. 5 (2023): 857–870.

[46] S. De Braganca, M. S. Dillingham, and F. Moreno-Herrero, “Recent Insights Into Eukaryotic Double-Strand DNA Break Repair Unveiled by Single-Molecule Methods,” Trends in Genetics 39, no. 12 (2023): 924–940.

[47] Y. Liu, W. T. Cottle, and T. Ha, “Mapping Cellular Responses to DNA Double-Strand Breaks Using CRISPR Technologies,” Trends in Genetics 39, no. 7 (2023): 560–574.

[48] J. Deng, Y. Li, L. Yin, et al., “Histone Lactylation Enhances GCLC Expression and Thus Promotes Chemoresistance of Colorectal Cancer Stem Cells Through Inhibiting Ferroptosis,” Cell Death & Disease 16, no. 1 (2025): 193.

[49] D. Liang, A. M. Minikes, and X. Jiang, “Ferroptosis at the Intersection of Lipid Metabolism and Cellular Signaling,” Molecular Cell 82, no. 12 (2022): 2215–2227.

[50] F. Li, H. Zhang, Y. Huang, et al., “Single-Cell Transcriptome Analysis Reveals the Association Between Histone Lactylation and Cisplatin Resistance in Bladder Cancer,” Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 73 (2024): 101059.

[51] L. Zhao, R. Li, and Y. H. Gan, “Knockdown of Yin Yang 1 Enhances Anticancer Effects of Cisplatin Through Protein Phosphatase 2A-Mediated T308 Dephosphorylation of AKT,” Cell Death & Disease 9, no. 7 (2018): 747.

[52] X. Hong, Q. Li, J. Li, et al., “CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 28, no. 20 (2022): 4521–4535.

[53] Y. D. Chu, L. C. Cheng, S. N. Lim, M. W. Lai, C. T. Yeh, and W. R. Lin, “Aldolase B-Driven Lactagenesis and CEACAM6 Activation Promote Cell Renewal and Chemoresistance in Colorectal Cancer Through the Warburg Effect,” Cell Death & Disease 14, no. 10 (2023): 660.

[54] X. Sun, L. He, H. Liu, et al., “The Diapause-Like Colorectal Cancer Cells Induced by SMC4 Attenuation are Characterized by Low Proliferation and Chemotherapy Insensitivity,” Cell Metabolism 35, no. 9 (2023): 1563–1579.

[55] C. Bailly, “Irinotecan: 25 Years of Cancer Treatment,” Pharmacological Research 148 (2019): 104398.

[56] W. Duan, W. Liu, S. Xia, et al., “Warburg Effect Enhanced by AKR1B10 Promotes Acquired Resistance to Pemetrexed in Lung Cancer-Derived Brain Metastasis,” Journal of Translational medicine 21, no. 1 (2023): 547.

[57] S. Cheng, L. Chen, J. Ying, et al., “20(S)-Ginsenoside Rh2 Ameliorates ATRA Resistance in APL by Modulating Lactylation-Driven METTL3,” Journal of Ginseng Research 48, no. 3 (2024): 298–309.

[58] Y. Zeng, H. Jiang, Z. Chen, et al., “Histone Lactylation Promotes Multidrug Resistance in Hepatocellular Carcinoma by Forming a Positive Feedback Loop With PTEN,” Cell Death & Disease 16, no. 1 (2025): 59.

[59] A. Christine, M. K. Park, S. J. Song, and M. S. Song, “The Equilibrium of Tumor Suppression: DUBs as Active Regulators of PTEN,” Experimental & Molecular Medicine 54, no. 11 (2022): 1814–1821.

[60] C. Zheng, H. Tan, G. Niu, et al., “ACAT1-Mediated ME2 Acetylation Drives Chemoresistance in Ovarian Cancer by Linking Glutaminolysis to Lactate Production,” Advanced Science 12, no. 14 (2025): e2416467.

[61] L. Ippolito, A. Morandi, E. Giannoni, and P. Chiarugi, “Lactate: A Metabolic Driver in the Tumour Landscape,” Trends in Biochemical Sciences 44, no. 2 (2019): 153–166.

[62] E. M. E. Barnes, Y. Xu, A. Benito, et al., “Lactic Acidosis Induces Resistance to the Pan-Akt Inhibitor Uprosertib in Colon Cancer Cells,” British Journal of Cancer 122, no. 9 (2020): 1298–1308.

[63] J. S. Lorente, A. V. Sokolov, G. Ferguson, H. B. Schioth, A. S. Hauser, and D. E. Gloriam, “GPCR Drug Discovery: New Agents, Targets and Indications,” Nature Reviews Drug Discovery 24, no. 6 (2025): 458–479.

[64] M. Bekes, D. R. Langley, and C. M. Crews, “PROTAC Targeted Protein Degraders: The Past Is Prologue,” Nature Reviews Drug Discovery 21, no. 3 (2022): 181–200.

[65] H. Hong, H. Han, L. Wang, et al., “ABCF1-K430-Lactylation Promotes HCC Malignant Progression via Transcriptional Activation of HIF1 Signaling Pathway,” Cell Death and Differentiation 32, no. 4 (2025): 613–631.

[66] X. Wang, Y. Shi, H. Shi, et al., “MUC20 Regulated by Extrachromosomal Circular DNA Attenuates Proteasome Inhibitor Resistance of Multiple Myeloma by Modulating Cuproptosis,” Journal of Experimental & Clinical Cancer Research: CR 43, no. 1 (2024): 68.

[67] M. Xing, Q. Zhang, and W. Song, “GIGYF1-Disturbed IGF-1R Recycling: A Potential Contributor to Autism Spectrum Disorder Pathogenesis?,” Journal of Clinical Investigation 132, no. 19 (2022): e163553.

[68] L. Ma, W. Zhao, S. Huang, et al., “IGF/IGF-1R Signal Pathway in Pain: A Promising Therapeutic Target,” International Journal of Biological Sciences 19, no. 11 (2023): 3472–3482.

[69] B. Patino-Escobar, A. Talbot, and A. P. Wiita, “Overcoming Proteasome Inhibitor Resistance in the Immunotherapy Era,” Trends in Pharmacological Sciences 44, no. 8 (2023): 507–518.

[70] Z. Yang, W. Su, Q. Zhang, et al., “Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer,” Advanced Science 12, no. 12 (2025): e2408845.

[71] A. Li, Z. Gong, Y. Long, et al., “Lactylation of LSD1 Is an Acquired Epigenetic Vulnerability of BRAFi/MEKi-Resistant Melanoma,” Developmental Cell 60, no. 14 (2025): 1974–1990.

[72] R. P. Patel, L. R. J. Lim, R. Saleh, et al., “Sensitivity to Immune Checkpoint Inhibitors in BRAF/MEK Inhibitor Refractory Melanoma,” Journal for Immunotherapy of Cancer 13, no. 5 (2025): e011551.

[73] W. Li, C. Zhou, L. Yu, et al., “Tumor-Derived Lactate Promotes Resistance to Bevacizumab Treatment by Facilitating Autophagy Enhancer Protein RUBCNL Expression Through Histone H3 Lysine 18 Lactylation (H3K18la) in Colorectal Cancer,” Autophagy 20, no. 1 (2024): 114–130.

[74] J. Debnath, N. Gammoh, and K. M. Ryan, “Autophagy and Autophagy-Related Pathways in Cancer,” Nature Reviews Molecular Cell Biology 24, no. 8 (2023): 560–575.

[75] J. Dai, X. Lu, C. Zhang, et al., “NNMT Promotes Acquired EGFR-TKI Resistance by Forming EGR1 and Lactate-Mediated Double Positive Feedback Loops in Non-Small Cell Lung Cancer,” Molecular Cancer 24, no. 1 (2025): 79.

[76] R. Dong, Y. Fei, Y. He, et al., “Lactylation-Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib,” Advanced Science 12, no. 15 (2025): e2412559.

[77] B. Lu, S. Chen, X. Guan, et al., “Lactate Accumulation Induces H4K12la to Activate Super-Enhancer-Driven RAD23A Expression and Promote Niraparib Resistance in Ovarian Cancer,” Molecular Cancer 24, no. 1 (2025): 83.

[78] N. Zhang, Y. Zhang, J. Xu, et al., “α-Myosin Heavy Chain Lactylation Maintains Sarcomeric Structure and Function and Alleviates the Development of Heart Failure,” Cell Research 33, no. 9 (2023): 679–698.

[79] E. M. McNally, “Beta-Myosin Heavy Chain Gene Mutations in Familial Hypertrophic Cardiomyopathy: The Usual Suspect?,” Circulation Research 90, no. 3 (2002): 246–247.

[80] M. Apicella, E. Giannoni, S. Fiore, et al., “Increased Lactate Secretion by Cancer Cells Sustains Non-Cell-Autonomous Adaptive Resistance to MET and EGFR Targeted Therapies,” Cell Metabolism 28, no. 6 (2018): 848–865.

[81] A. Morrot, L. M. da Fonseca, E. J. Salustiano, et al., “Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses,” Frontiers in Oncology 8 (2018): 81.

[82] D. J. Baker, Z. Arany, J. A. Baur, J. A. Epstein, and C. H. June, “CAR T Therapy Beyond Cancer: The Evolution of a Living Drug,” Nature 619, no. 7971 (2023): 707–715.

[83] J. Lu and G. Jiang, “The Journey of CAR-T Therapy in Hematological Malignancies,” Molecular Cancer 21, no. 1 (2022): 194.

[84] X. Xia, Z. Yang, Q. Lu, et al., “Reshaping the Tumor Immune Microenvironment to Improve CAR-T Cell-Based Cancer Immunotherapy,” Molecular Cancer 23, no. 1 (2024): 175.

[85] K. Lungova and M. Putman, “Barriers to CAR T-Cell Therapy in Rheumatology,” Lancet Rheumatology 7, no. 3 (2025): e212–e216.

[86] C. Xia, S. Yin, K. K. W. To, and L. Fu, “CD39/CD73/A2AR Pathway and Cancer Immunotherapy,” Molecular Cancer 22, no. 1 (2023): 44.

[87] J. Shen, B. Liao, L. Gong, et al., “CD39 and CD73: Biological Functions, Diseases and Therapy,” Molecular Biomedicine 6, no. 1 (2025): 97.

[88] Z. Li, P. Si, T. Meng, et al., “CCR8(+) Decidual Regulatory T Cells Maintain Maternal-Fetal Immune Tolerance During Early Pregnancy,” Science Immunology 10, no. 106 (2025): eado2463.

[89] Y. Wen, Y. Xia, X. Yang, H. Li, and Q. Gao, “CCR8: A Promising Therapeutic Target Against Tumor-Infiltrating Regulatory T Cells,” Trends in Immunology 46, no. 2 (2025): 153–165.

[90] S. Dikiy and A. Y. Rudensky, “Principles of Regulatory T Cell Function,” Immunity 56, no. 2 (2023): 240–255.

[91] X. Song, R. Chen, J. Li, et al., “Fragile Treg Cells: Traitors in Immune Homeostasis?,” Pharmacological Research 206 (2024): 107297.

[92] G. Escobar, T. R. Berger, and M. V. Maus, “CAR-T Cells in Solid Tumors: Challenges and Breakthroughs,” Cell Reports Medicine 6, no. 11 (2025): 102353.

[93] T. Sun, B. Liu, Y. Li, et al., “Oxamate Enhances the Efficacy of CAR-T Therapy Against Glioblastoma via Suppressing Ectonucleotidases and CCR8 Lactylation,” Journal of Experimental & Clinical Cancer Research: CR 42, no. 1 (2023): 253.

[94] L. A. Dempsey, “STAT5 facts,” Nature Immunology 24, no. 1 (2023): 1.

[95] Z. W. Huang, X. N. Zhang, L. Zhang, et al., “STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 391.

[96] K. Pang, Z. D. Shi, L. Y. Wei, et al., “Research Progress of Therapeutic Effects and Drug Resistance of Immunotherapy Based on PD-1/PD-L1 Blockade,” Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 66 (2023): 100907.

[97] G. Kochan, “PD-L1, a Master Regulator of Immunity 20,” International Journal of Molecular Sciences 24, no. 5 (2023): 4385.

[98] K. Aliazis, A. Christofides, R. Shah, et al., “The Tumor Microenvironment's Role in the Response to Immune Checkpoint Blockade,” Nature Cancer 6, no. 6 (2025): 924–937.

[99] G. R. Khosravi, S. Mostafavi, S. Bastan, N. Ebrahimi, R. S. Gharibvand, and N. Eskandari, “Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot,” Cancer Communications 44, no. 5 (2024): 521–553.

[100] J. Abramson, J. Dobeš, M. Lyu, and G. F. Sonnenberg, “The Emerging Family of RORγt(+) Antigen-Presenting Cells,” Nature Reviews Immunology 24, no. 1 (2024): 64–77.

[101] J. Chen and B. P. Rosen, “Arsenite Methyltransferase Diversity and Optimization of Methylation Efficiency,” Environmental Science & Technology 57, no. 26 (2023): 9754–9761.

[102] W. Chen, P. Wang, Y. Xie, et al., “Histone Lactylation-Augmented IRF4 Is Implicated in Arsenite-Induced Liver Fibrosis via Modulating Th17 Cell Differentiation,” Chemico-Biological Interactions 414 (2025): 111507.

[103] M. Song, J. Liang, L. Wang, et al., “IL-17A Functions and the Therapeutic Use of IL-17A and IL-17RA Targeted Antibodies for Cancer Treatment,” International Immunopharmacology 123 (2023): 110757.

[104] T. Kanno, T. Nakajima, K. Miyako, and Y. Endo, “Lipid Metabolism in Th17 Cell Function,” Pharmacology & Therapeutics 245 (2023): 108411.

[105] H. Liao, X. Chang, L. Gao, et al., “IL-17A Promotes Tumorigenesis and Upregulates PD-L1 Expression in Non-Small Cell Lung Cancer,” Journal of Translational Medicine 21, no. 1 (2023): 828.

[106] J. Xiong, J. He, J. Zhu, et al., “Lactylation-Driven METTL3-Mediated RNA m(6)A Modification Promotes Immunosuppression of Tumor-Infiltrating Myeloid Cells,” Molecular Cell 82, no. 9 (2022): 1660–1677.

[107] S. Cheng, Z. Li, R. Gao, et al., “A Pan-Cancer Single-Cell Transcriptional Atlas of Tumor Infiltrating Myeloid Cells,” Cell 184, no. 3 (2021): 792–809.

[108] B. Xu, Y. Liu, N. Li, and Q. Geng, “Lactate and Lactylation in Macrophage Metabolic Reprogramming: Current Progress and Outstanding Issues,” Frontiers in Immunology 15 (2024): 1395786.

[109] K. Chaudagar, H. M. Hieromnimon, R. Khurana, et al., “Reversal of Lactate and PD-1-Mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-Deficient Prostate Cancer,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 29, no. 10 (2023): 1952–1968.

[110] X. Chu, Y. Tian, and C. Lv, “Decoding the Spatiotemporal Heterogeneity of Tumor-Associated Macrophages,” Molecular Cancer 23, no. 1 (2024): 150.

[111] L. Merkens, V. Sailer, D. Lessel, et al., “Aggressive Variants of Prostate Cancer: Underlying Mechanisms of Neuroendocrine Transdifferentiation,” Journal of Experimental & Clinical Cancer Research: CR 41, no. 1 (2022): 46.

[112] K. Chaudagar, H. M. Hieromnimon, A. Kelley, et al., “Suppression of Tumor Cell Lactate-Generating Signaling Pathways Eradicates Murine PTEN/p53-Deficient Aggressive-Variant Prostate Cancer via Macrophage Phagocytosis,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 29, no. 23 (2023): 4930–4940.

[113] C. Chester, M. F. Sanmamed, J. Wang, and I. Melero, “Immunotherapy Targeting 4-1BB: Mechanistic Rationale, Clinical Results, and Future Strategies,” Blood 131, no. 1 (2018): 49–57.

[114] A. De Leo, A. Ugolini, X. Yu, et al., “Glucose-Driven Histone Lactylation Promotes the Immunosuppressive Activity of Monocyte-Derived Macrophages in Glioblastoma,” Immunity 57, no. 5 (2024): 1105–1123.

[115] F. J. Hansen, A. Mittelstädt, F. N. Clausen, et al., “CD71 Expressing Circulating Neutrophils Serve as a Novel Prognostic Biomarker for Metastatic Spread and Reduced Outcome in Pancreatic Ductal Adenocarcinoma Patients,” Scientific Reports 14, no. 1 (2024): 21164.

[116] A. Ugolini, A. De Leo, X. Yu, et al., “Functional Reprogramming of Neutrophils Within the Brain Tumor Microenvironment by Hypoxia-Driven Histone Lactylation,” Cancer Discovery 15, no. 6 (2025): 1270–1296.

[117] H. Cai, X. Chen, Y. Liu, et al., “Lactate Activates Trained Immunity by Fueling the Tricarboxylic Acid Cycle and Regulating Histone Lactylation,” Nature Communications 16, no. 1 (2025): 3230.

[118] Q. Yang, C. Guo, and L. Zhang, “The Role of Metabolite Sensors in Metabolism-Immune Interaction: New Targets for Immune Modulation,” Clinical and Translational Medicine 15, no. 4 (2025): e70294.

[119] Z. Zhang and C. Zhang, “Regulation of cGAS-STING Signalling and Its Diversity of Cellular Outcomes,” Nature Reviews Immunology 25, no. 6 (2025): 425–444.

[120] B. Zhang, P. Xu, and A. Ablasser, “Regulation of the cGAS-STING Pathway,” Annual Review of Immunology 43, no. 1 (2025): 667–692.

[121] N. Samson and A. Ablasser, “The cGAS-STING Pathway and Cancer,” Nature Cancer 3, no. 12 (2022): 1452–1463.

[122] S. Min, X. Zhang, Y. Liu, et al., “Personalized Treatment Decision-Making Using a Machine Learning-Derived Lactylation Signature for Breast Cancer Prognosis,” Frontiers in Immunology 16 (2025): 1540018.

[123] H. Gong, H. Zhong, L. Cheng, L. P. Li, and D. K. Zhang, “Post-Translational Protein Lactylation Modification in Health and Diseases: A Double-Edged Sword,” Journal of Translational Medicine 22, no. 1 (2024): 41.

[124] Z. Wu and J. Jankowski, “Impact of Post-Translational Modification on the Genesis and Progression of Diseases,” Molecular Aspects of Medicine 86 (2022): 101105.

[125] M. Shvedunova and A. Akhtar, “Modulation of cellular processes by histone and non-histone protein acetylation,” Nature Reviews Molecular Cell Biology 23, no. 5 (2022): 329–349.

[126] N. Kitamura and J. J. Galligan, “A Global View of the Human Post-Translational Modification Landscape,” Biochemical Journal 480, no. 16 (2023): 1241–1265.

[127] F. SM, L. Abrami, M. E. Linder, S. X. Bamji, B. C. Dickinson, and F. G. van der Goot, “Mechanisms and Functions of Protein S-Acylation,” Nature Reviews Molecular Cell Biology 25, no. 6 (2024): 488–509.

[128] M. S. Hwang, J. Park, Y. Ham, I. H. Lee, and K. H. Chun, “Roles of Protein Post-Translational Modifications during Adipocyte Senescence,” International Journal of Biological Sciences 19, no. 16 (2023): 5245–5256.

[129] K. Pang, W. Wang, J. X. Qin, et al., “Role of Protein Phosphorylation in Cell Signaling, Disease, and the Intervention Therapy,” MedComm 3, no. 4 (2022): e175.

[130] J. D. Graves and E. G. Krebs, “Protein Phosphorylation and Signal Transduction,” Pharmacology & Therapeutics 82, no. 2–3 (1999): 111–121.

[131] T. Bilbrough, E. Piemontese, and O. Seitz, “Dissecting the Role of Protein Phosphorylation: A Chemical Biology Toolbox,” Chemical Society Reviews 51, no. 13 (2022): 5691–5730.

[132] L. N. Johnson, “The Regulation of Protein Phosphorylation,” Biochemical Society Transactions 37, no. Pt 4 (2009): 627–641.

[133] R. Liu, Z. Zou, L. Chen, et al., “FKBP10 Promotes Clear Cell Renal Cell Carcinoma Progression and Regulates Sensitivity to the HIF2alpha Blockade by Facilitating LDHA Phosphorylation,” Cell Death & Disease 15, no. 1 (2024): 64.

[134] J. Liu, C. Zhang, T. Zhang, et al., “Metabolic Enzyme LDHA Activates Rac1 GTPase as a Noncanonical Mechanism to Promote Cancer,” Nature Metabolism 4, no. 12 (2022): 1830–1846.

[135] M. Jia, X. Yue, W. Sun, et al., “ULK1-Mediated Metabolic Reprogramming Regulates Vps34 Lipid Kinase Activity by its Lactylation,” Science Advances 9, no. 22 (2023): eadg4993.

[136] T. Narita, B. T. Weinert, and C. Choudhary, “Functions and Mechanisms of Non-Histone Protein Acetylation,” Nature Reviews Molecular Cell Biology 20, no. 3 (2019): 156–174.

[137] K. J. Menzies, H. Zhang, E. Katsyuba, and J. Auwerx, “Protein Acetylation in Metabolism—Metabolites and Cofactors,” Nature Reviews Endocrinology 12, no. 1 (2016): 43–60.

[138] Á. Marín-Hernández, J. S. Rodríguez-Zavala, R. Jasso-Chávez, E. Saavedra, and R. Moreno-Sánchez, “Protein Acetylation Effects on Enzyme Activity and Metabolic Pathway Fluxes,” Journal of Cellular Biochemistry 123, no. 4 (2022): 701–718.

[139] M. M. Zhou and P. A. Cole, “Targeting Lysine Acetylation Readers and Writers,” Nature Reviews Drug Discovery 24, no. 2 (2025): 112–133.

[140] J. Yang, C. Song, and X. Zhan, “The Role of Protein Acetylation in Carcinogenesis and Targeted Drug Discovery,” Frontiers in Endocrinology 13 (2022): 972312.

[141] H. Rho, A. R. Terry, C. Chronis, and N. Hay, “Hexokinase 2-Mediated Gene Expression via Histone Lactylation is Required for Hepatic Stellate Cell Activation and Liver Fibrosis,” Cell Metabolism 35, no. 8 (2023): 1406–1423.

[142] S. An, Y. Yao, H. Hu, et al., “PDHA1 Hyperacetylation-Mediated Lactate Overproduction Promotes Sepsis-Induced Acute Kidney Injury via Fis1 Lactylation,” Cell Death & Disease 14, no. 7 (2023): 457.

[143] Z. Yang, Y. Zheng, and Q. Gao, “Lysine Lactylation in the Regulation of Tumor Biology,” Trends in Endocrinology and Metabolism 35, no. 8 (2024): 720–731.

[144] R. Gao, Y. Li, Z. Xu, et al., “Mitochondrial Pyruvate Carrier 1 Regulates Fatty Acid Synthase Lactylation and Mediates Treatment of Nonalcoholic Fatty Liver Disease,” Hepatology 78, no. 6 (2023): 1800–1815.

[145] P. Paiva, F. E. Medina, M. Viegas, et al., “Animal Fatty Acid Synthase: A Chemical Nanofactory,” Chemical Reviews 121, no. 15 (2021): 9502–9553.

[146] D. Buckley, G. Duke, T. S. Heuer, et al., “Fatty Acid Synthase—Modern Tumor Cell Biology Insights Into a Classical Oncology Target,” Pharmacology & Therapeutics 177 (2017): 23–31.

[147] L. Cerchietti, “Genetic Mechanisms Underlying Tumor Microenvironment Composition and Function in Diffuse Large B-Cell Lymphoma,” Blood 143, no. 12 (2024): 1101–1111.

[148] L. Sun, H. Zhang, and P. Gao, “Metabolic Reprogramming and Epigenetic Modifications on the Path to Cancer,” Protein & Cell 13, no. 12 (2022): 877–919.

[149] C. Zhou, W. Li, Z. Liang, et al., “Mutant KRAS-Activated CircATXN7 Fosters Tumor Immunoescape by Sensitizing Tumor-Specific T Cells to Activation-Induced Cell Death,” Nature Communications 15, no. 1 (2024): 499.

[150] Q. Guo, Y. Jin, and X. Chen, “NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 53.

[151] J. D. Klement, P. S. Redd, C. Lu, et al., “Tumor PD-L1 Engages Myeloid PD-1 to Suppress Type I Interferon to Impair Cytotoxic T Lymphocyte Recruitment,” Cancer Cell 41, no. 3 (2023): 620–636.

[152] M. Buckley, C. Terwagne, A. Ganner, et al., “Saturation Genome Editing Maps the Functional Spectrum of Pathogenic VHL Alleles,” Nature Genetics 56, no. 7 (2024): 1446–1455.

[153] S. K. Tan, H. Y. Hougen, J. R. Merchan, M. L. Gonzalgo, and S. M. Welford, “Fatty Acid Metabolism Reprogramming in ccRCC: Mechanisms and Potential Targets,” Nature Reviews Urology 20, no. 1 (2023): 48–60.

[154] A. J. Majmundar, W. J. Wong, and M. C. Simon, “Hypoxia-Inducible Factors and the Response to Hypoxic Stress,” Molecular Cell 40, no. 2 (2010): 294–309.

[155] J. Yang, L. Luo, C. Zhao, et al., “A Positive Feedback Loop Between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression,” International Journal of Biological Sciences 18, no. 8 (2022): 3470–3483.

[156] O. Hassin and M. Oren, “Drugging p53 in Cancer: One Protein, Many Targets,” Nature Reviews Drug Discovery 22, no. 2 (2023): 127–144.

[157] S. Peuget, X. Zhou, and G. Selivanova, “Translating p53-Based Therapies for Cancer Into the Clinic,” Nature Reviews Cancer 24, no. 3 (2024): 192–215.

[158] I. Dutto, C. Scalera, M. Tillhon, et al., “Mutations in CREBBP and EP300 Genes Affect DNA Repair of Oxidative Damage in Rubinstein-Taybi Syndrome Cells,” Carcinogenesis 41, no. 3 (2020): 257–266.

[159] R. Wang, T. M. Fortier, F. Chai, et al., “PINK1, Keap1, and Rtnl1 Regulate Selective Clearance of Endoplasmic Reticulum During Development,” Cell 186, no. 19 (2023): 4172–4188.

[160] F. Reggiori and M. Molinari, “ER-phagy: Mechanisms, Regulation, and Diseases Connected to the Lysosomal Clearance of the Endoplasmic Reticulum,” Physiological Reviews 102, no. 3 (2022): 1393–1448.

[161] R. A. Saxton, N. Tsutsumi, L. L. Su, et al., “Structure-Based Decoupling of the Pro- and Anti-Inflammatory Functions of Interleukin-10,” Science 371, no. 6535 (2021): eabc8433.

[162] D. Wang, G. Du, X. Chen, et al., “Zeb1-Controlled Metabolic Plasticity Enables Remodeling of Chromatin Accessibility in the Development of Neuroendocrine Prostate Cancer,” Cell Death and Differentiation 31, no. 6 (2024): 779–791.

[163] H. Swahn, K. Li, T. Duffy, et al., “Senescent Cell Population With ZEB1 Transcription Factor as Its Main Regulator Promotes Osteoarthritis in Cartilage and Meniscus,” Annals of the Rheumatic Diseases 82, no. 3 (2023): 403–415.

[164] X. Zhang, Y. Li, and Y. Chen, “Development of a Comprehensive Gene Signature Linking Hypoxia, Glycolysis, Lactylation, and Metabolomic Insights in Gastric Cancer Through the Integration of Bulk and Single-Cell RNA-Seq Data,” Biomedicines 11, no. 11 (2023): 2948.

[165] J. Zhou, W. Xu, Y. Wu, et al., “GPR37 Promotes Colorectal Cancer Liver Metastases by Enhancing the Glycolysis and Histone Lactylation via Hippo Pathway,” Oncogene 42, no. 45 (2023): 3319–3330.

[166] S. Wang, J. Bai, Y. L. Zhang, et al., “CXCL1-CXCR2 Signalling Mediates Hypertensive Retinopathy by Inducing Macrophage Infiltration,” Redox Biology 56 (2022): 102438.

[167] J. J. Pan, S. Z. Xie, X. Zheng, et al., “Acetyl-CoA Metabolic Accumulation Promotes Hepatocellular Carcinoma Metastasis via Enhancing CXCL1-Dependent Infiltration of Tumor-Associated Neutrophils,” Cancer Letters 592 (2024): 216903.

[168] W. Zhang, H. Wang, M. Sun, et al., “CXCL5/CXCR2 Axis in Tumor Microenvironment as Potential Diagnostic Biomarker and Therapeutic Target,” Cancer Communications 40, no. 2–3 (2020): 69–80.

[169] R. Zeng, H. Gou, H. C. H. Lau, and J. Yu, “Stomach Microbiota in Gastric Cancer Development and Clinical Implications,” Gut 73, no. 12 (2024): 2062–2073.

[170] Y. C. Chen, P. Malfertheiner, H. T. Yu, et al., “Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022,” Gastroenterology 166, no. 4 (2024): 605–619.

[171] T. Zhang, Y. Li, E. Zhai, et al., “Intratumoral Fusobacterium nucleatum Recruits Tumor-Associated Neutrophils to Promote Gastric Cancer Progression and Immune Evasion,” Cancer Research 85, no. 10 (2025): 1819–1841.

[172] F. Sommer, J. M. Anderson, R. Bharti, J. Raes, and P. Rosenstiel, “The Resilience of the Intestinal Microbiota Influences Health and Disease,” Nature Reviews Microbiology 15, no. 10 (2017): 630–638.

[173] R. Nasr, A. Shamseddine, D. Mukherji, F. Nassar, and S. Temraz, “The Crosstalk Between Microbiome and Immune Response in Gastric Cancer,” International Journal of Molecular Sciences 21, no. 18 (2020): 6586.

[174] T. Kawai, M. Ikegawa, D. Ori, and S. Akira, “Decoding Toll-Like Receptors: Recent Insights and Perspectives in Innate Immunity,” Immunity 57, no. 4 (2024): 649–673.

[175] I. M. L. Saur, R. Panstruga, and P. Schulze-Lefert, “NOD-Like Receptor-Mediated Plant Immunity: From Structure to Cell Death,” Nature Reviews Immunology 21, no. 5 (2021): 305–318.

[176] M. Sauer and N. S. Han, “Lactic Acid Bacteria: Little Helpers for Many Human Tasks,” Essays in Biochemistry 65, no. 2 (2021): 163–171.

[177] M. S. Riaz Rajoka, J. Shi, J. Zhu, et al., “Capacity of Lactic Acid Bacteria in Immunity Enhancement and Cancer Prevention,” Applied Microbiology and Biotechnology 101, no. 1 (2017): 35–45.

[178] K. Garbacz, “Anticancer Activity of Lactic Acid Bacteria,” Seminars in Cancer Biology 86, no. Pt 3 (2022): 356–366.

[179] K. Vinasco, H. M. Mitchell, N. O. Kaakoush, and N. Castaño-Rodríguez, “Microbial Carcinogenesis: Lactic Acid Bacteria in Gastric Cancer,” Biochimica et Biophysica Acta Reviews on Cancer 1872, no. 2 (2019): 188309.

[180] C. N. S. Allen, S. P. Arjona, M. Santerre, and B. E. Sawaya, “Hallmarks of Metabolic Reprogramming and Their Role in Viral Pathogenesis,” Viruses 14, no. 3 (2022): 602.

[181] Q. Yan, J. Zhou, Y. Gu, et al., “Lactylation of NAT10 Promotes N(4)-Acetylcytidine Modification on tRNA(Ser-CGA-1-1) to Boost Oncogenic DNA Virus KSHV Reactivation,” Cell Death and Differentiation 31, no. 10 (2024): 1362–1374.

[182] S. Seetharaman, B. Vianay, V. Roca, et al., “Microtubules Tune Mechanosensitive Cell Responses,” Nature Materials 21, no. 3 (2022): 366–377.

[183] Q. Meng, Y. Zhang, H. Sun, et al., “Human Papillomavirus-16 E6 Activates the Pentose Phosphate Pathway to Promote Cervical Cancer Cell Proliferation by Inhibiting G6PD Lactylation,” Redox Biology 71 (2024): 103108.

[184] Z. Yan, Z. Zhang, Y. Chen, J. Xu, J. Wang, and Z. Wang, “Enhancing Cancer Therapy: The Integration of Oncolytic Virus Therapy With Diverse Treatments,” Cancer Cell International 24, no. 1 (2024): 242.

[185] B. E. Kennedy, M. Sadek, and S. A. Gujar, “Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy,” Molecular Therapy: The Journal of the American Society of Gene Therapy 28, no. 6 (2020): 1417–1421.

[186] K. DePeaux and G. M. Delgoffe, “Integrating Innate and Adaptive Immunity in Oncolytic Virus Therapy,” Trends in Cancer 10, no. 2 (2024): 135–146.

[187] B. Zhao, Z. Lan, C. Li, and H. Wang, “Roles of Lactylation in Lipid Metabolism and Related Diseases,” Cell Death Discovery 11, no. 1 (2025): 401.

[188] Q. Chen, Y. Wang, L. Yang, et al., “PM2.5 Promotes NSCLC Carcinogenesis Through Translationally and Transcriptionally Activating DLAT-Mediated Glycolysis Reprograming,” Journal of Experimental & Clinical Cancer Research: CR 41, no. 1 (2022): 229.

[189] X. Fan, T. Dong, K. Yan, X. Ci, and L. Peng, “PM2.5 Increases Susceptibility to Acute Exacerbation of COPD via NOX4/Nrf2 Redox Imbalance-Mediated Mitophagy,” Redox Biology 59 (2023): 102587.

[190] Z. Liu, W. Liu, H. Wei, et al., “Elevated Lactate Production Exacerbates PM2.5-Induced Pulmonary Fibrosis by Stabilizing TGF-β1,” Journal of Advanced Research (2025).

[191] C. P. Bracken and G. J. Goodall, “The Many Regulators of Epithelial-Mesenchymal Transition,” Nature Reviews Molecular Cell Biology 23, no. 2 (2022): 89–90.

[192] G. Manfioletti and M. Fedele, “Epithelial-Mesenchymal Transition (EMT),” International Journal of Molecular Sciences 24, no. 14 (2023): 11386.

[193] S. Halford, G. J. Veal, S. R. Wedge, et al., “A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients With Advanced Cancer,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 29, no. 8 (2023): 1429–1439.

[194] M. Beloueche-Babari, T. Casals Galobart, and T. Delgado-Goni, “Monocarboxylate Transporter 1 Blockade With AZD3965 Inhibits Lipid Biosynthesis and Increases Tumour Immune Cell Infiltration,” British Journal of Cancer 122, no. 6 (2020): 895–903.

[195] Y. F. Chen, A. Rahman, J. L. Sax, M. J. Atala Pleshinger, R. M. Friedrich, and D. J. Adams, “C646 Degrades Exportin-1 to Modulate p300 Chromatin Occupancy and Function,” Cell Chemical Biology 31, no. 7 (2024): 1363–1372.

[196] M. Strachowska and A. Robaszkiewicz, “Characteristics of Anticancer Activity of CBP/p300 Inhibitors—Features of Their Classes, Intracellular Targets and Future Perspectives of Their Application in Cancer Treatment,” Pharmacology & Therapeutics 257 (2024): 108636.

[197] X. Y. Xiong, X. R. Pan, X. X. Luo, et al., “Astrocyte-Derived Lactate Aggravates Brain Injury of Ischemic Stroke in Mice by Promoting the Formation of Protein Lactylation,” Theranostics 14, no. 11 (2024): 4297–4317.

[198] L. M. Lasko, C. G. Jakob, R. P. Edalji, et al., “Discovery of a Selective Catalytic p300/CBP Inhibitor That Targets Lineage-Specific Tumours,” Nature 550, no. 7674 (2017): 128–132.

[199] P. Gou and W. Zhang, “Protein Lysine Acetyltransferase CBP/p300: A Promising Target for Small Molecules in Cancer Treatment,” Biomedicine & Pharmacotherapy 171 (2024): 116130.

[200] M. Song, B. Liu, H. Wang, and W. Sun, “Lactate Metabolism and Lactylation Modification: New Opportunities and Challenges in Cardiovascular Disease,” MedComm 6, no. 7 (2025): e70269.

[201] Y. Rao, S. Gammon, N. M. Zacharias, et al., “Hyperpolarized [1-13C]Pyruvate-to-[1-13C]Lactate Conversion Is Rate-Limited by Monocarboxylate Transporter-1 in the Plasma Membrane,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 36 (2020): 22378–22389.

[202] N. Sushentsev, G. Hamm, J. Richings, et al., “Imaging Tumor Lactate Is Feasible for Identifying Intermediate-Risk Prostate Cancer Patients With Postsurgical Biochemical Recurrence,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 49 (2023): e2312261120.

[203] F. Pan, X. Liu, J. Wan, et al., “Advances and Prospects in Deuterium Metabolic Imaging (DMI): A Systematic Review of in Vivo Studies,” European Radiology Experimental 8, no. 1 (2024): 65.

[204] K. Shirbandi, R. Rikhtegar, M. Khalafi, et al., “Functional Magnetic Resonance Spectroscopy of Lactate in Alzheimer Disease: A Comprehensive Review of Alzheimer Disease Pathology and the Role of Lactate,” Topics in Magnetic Resonance Imaging 32, no. 2 (2023): 15–26.

[205] P. Herrero, C. S. Dence, A. R. Coggan, Z. Kisrieva-Ware, P. Eisenbeis, and R. J. Gropler, “L-3-11C-Lactate as a PET Tracer of Myocardial Lactate Metabolism: A Feasibility Study,” Journal of Nuclear Medicine 48, no. 12 (2007): 2046–2055.

[206] K. Neumann, R. Flavell, and D. M. Wilson, “Exploring Metabolism in Vivo Using Endogenous 11C Metabolic Tracers,” Seminars in Nuclear Medicine 47, no. 5 (2017): 461–473.

[207] M. Cai, H. Liu, C. Shao, et al., “Metabolomics and Metabolites in Cancer Diagnosis and Treatment,” Molecular Biomedicine 6, no. 1 (2025): 109.

[208] S. Jiang, H. Li, L. Zhang, et al., “Generic Diagramming Platform (GDP): A Comprehensive Database of High-quality Biomedical Graphics,” Nucleic Acids Research 53, no. D1 (2025): D1670–D1676.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.